Unique offering VENDYS provides the only fully automated FDA-cleared office-based testing device for measuring vascular reactivity and endothelial function, presenting a strong differentiator to clinics seeking non-invasive cardiometabolic assessments.

Reimbursement potential Testing is reimbursable under Medicare and private payers, indicating a credible path for clinics to adopt with predictable revenue mechanics and potential for incremental patient visits.

Target customers Small medical practices and clinics focused on cardiovascular risk, metabolic health, and preventive care represent an accessible initial market given the device’s office-based format and rapid 5-minute test.

Clinical impact Real-time VRI reports empower clinicians to motivate patient adherence to therapies and lifestyle changes, suggesting opportunities for facility partnerships with weight management, hypertension, and preventive medicine programs.

Growth signals Revenue scale and proximity to large medical technology ecosystems imply potential collaborations or channel partnerships with major suppliers and distributors, expanding reach beyond solo practices.